Cargando…

SARS-CoV-2-specific CD4(+) T cells are associated with long-term persistence of neutralizing antibodies

Understanding the decay and maintenance of long-term SARS-CoV-2 neutralizing antibodies in infected or vaccinated people and how vaccines protect against other SARS-CoV-2 variants is critical for assessing public vaccination plans. Here, we measured different plasm antibody levels 2 and 12 months af...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wang, Zhongfang, Yang, Xiaoyun, Mei, Xinyue, Zhou, Yumin, Tang, Zhiqiang, Li, Guichang, Zhong, Jiaying, Yu, Mengqiu, Huang, Mingzhu, Su, Xiaoling, Lin, Bijia, Cao, Pengxing, Yang, Ji, Ran, Pixin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9034077/ https://www.ncbi.nlm.nih.gov/pubmed/35461307 http://dx.doi.org/10.1038/s41392-022-00978-0

Ejemplares similares

Exposure to SARS-CoV-2 generates T-cell memory in the absence of a detectable viral infection
por: Wang, Zhongfang, et al.
Publicado: (2021)

COVID-19 Severity Correlates with Weaker T-Cell Immunity, Hypercytokinemia, and Lung Epithelium Injury
por: Wang, Zhongfang, et al.
Publicado: (2020)

Heterologous boosting with third dose of coronavirus disease recombinant subunit vaccine increases neutralizing antibodies and T cell immunity against different severe acute respiratory syndrome coronavirus 2 variants
por: Zhao, Zhuxiang, et al.
Publicado: (2022)

SARS-CoV-2 vaccination-infection pattern imprints and diversifies T cell differentiation and neutralizing response against Omicron subvariants
por: Wang, Junxiang, et al.
Publicado: (2022)

Development of SARS‐CoV‐2 animal vaccines using a stable and efficient NDV expression system
por: He, Lei, et al.
Publicado: (2022)

The establishment of a cytomegalovirus -specific CD8(+) T-cell threshold by kinetic modeling for the prediction of post-hemopoietic stem cell transplant reactivation
por: Zhang, Jing, et al.
Publicado: (2022)

Heterologous booster with inhaled adenovirus vector COVID-19 vaccine generated more neutralizing antibodies against different SARS-CoV-2 variants
por: Zhong, Jiaying, et al.
Publicado: (2022)

High-dose N-acetylcysteine for long-term, regular treatment of early-stage chronic obstructive pulmonary disease (GOLD I–II): study protocol for a multicenter, double-blinded, parallel-group, randomized controlled trial in China
por: Tian, Heshen, et al.
Publicado: (2020)

Early intervention with tiotropium in Chinese patients with GOLD stages I–II chronic obstructive pulmonary disease (Tie-COPD): study protocol for a multicentre, double-blinded, randomised, controlled trial
por: Li, Xiaochen, et al.
Publicado: (2014)

On the Role of CD8(+) T Cells in Determining Recovery Time from Influenza Virus Infection
por: Cao, Pengxing, et al.
Publicado: (2016)

Analysis of pathological changes in the epithelium in COVID-19 patient airways
por: Yin, Wenguang, et al.
Publicado: (2021)

Persistence of the neutralizing antibody response after SARS-CoV-2 infection
por: Shim, Sang-Mu, et al.
Publicado: (2022)

SARS-CoV-2 spike protein: a key target for eliciting persistent neutralizing antibodies
por: Yang, Yang, et al.
Publicado: (2021)

Prevalence and characteristics of chronic obstructive pulmonary disease in China with a diagnostic criterion of FEV(1)/FVC less than the lower limit of normal—a reanalysis of Chinese epidemiological survey of COPD (CESCOPD) study
por: Liu, Sha, et al.
Publicado: (2021)

Asprosin-neutralizing antibodies as a treatment for metabolic syndrome
por: Mishra, Ila, et al.
Publicado: (2021)

Considerations for the Feasibility of Neutralizing Antibodies as a Surrogate Endpoint for COVID-19 Vaccines
por: Liu, Jianyang, et al.
Publicado: (2022)

Standardized neutralization antibody analytical procedure for clinical samples based on the AQbD concept
por: Liu, Jianyang, et al.
Publicado: (2023)

Robust neutralizing antibodies to SARS-CoV-2 infection persist for months
por: Wajnberg, Ania, et al.
Publicado: (2020)

Long‐term persistence of neutralizing SARS‐CoV‐2 antibodies in pets
por: Decaro, Nicola, et al.
Publicado: (2021)

The Pneumonia Severity Index as a Predictor of In-Hospital Mortality in Acute Exacerbation of Chronic Obstructive Pulmonary Disease
por: Hu, Guoping, et al.
Publicado: (2015)

Chronic exposure to biomass ambient particulate matter triggers alveolar macrophage polarization and activation in the rat lung
por: Wang, Shenlin, et al.
Publicado: (2022)

Recent advances in therapeutic applications of neutralizing antibodies for virus infections: an overview
por: Ali, Manasik Gumah, et al.
Publicado: (2020)

Clonally diverse CD38(+)HLA-DR(+)CD8(+) T cells persist during fatal H7N9 disease
por: Wang, Zhongfang, et al.
Publicado: (2018)

Long-term Persistence of Neutralizing Antibodies to SARS-CoV-2 Following Infection
por: Wisnivesky, Juan P., et al.
Publicado: (2021)

Generation and persistence of S1 IgG and neutralizing antibodies in post-COVID-19 patients
por: Guzmán-Martínez, Oscar, et al.
Publicado: (2021)

Progress of the COVID-19: Persistence, Effectiveness, and Immune Escape of the Neutralizing Antibody in Convalescent Serum
por: Liang, Dan, et al.
Publicado: (2022)

Crystal structure of CD27 in complex with a neutralizing noncompeting antibody
por: Teplyakov, Alexey, et al.
Publicado: (2017)

Structures of Omicron spike complexes and implications for neutralizing antibody development
por: Guo, Hangtian, et al.
Publicado: (2022)

Tiotropium discontinuation in patients with early-stage COPD: a prospective observational cohort study
por: Li, Chenglong, et al.
Publicado: (2019)

Computational characterization and design of SARS coronavirus receptor recognition and antibody neutralization
por: Zhang, Yuan, et al.
Publicado: (2007)

Neutralizing Antibody Response and SARS Severity
por: Ho, Mei-Shang, et al.
Publicado: (2005)

Long-term persistence of Chikungunya virus neutralizing antibodies in human populations of North Eastern Thailand
por: Nitatpattana, Narong, et al.
Publicado: (2014)

Persistence of neutralizing antibodies a year after SARS‐CoV‐2 infection in humans
por: Haveri, Anu, et al.
Publicado: (2021)

Quaternary Interaction of the HIV-1 Envelope Trimer with CD4 and Neutralizing Antibodies
por: Liu, Qingbo, et al.
Publicado: (2021)

Neutralizing antibodies for the prevention and treatment of COVID-19
por: Du, Lanying, et al.
Publicado: (2021)

Smad3‐mediated lncRNA HSALR1 enhances the non‐classic signalling pathway of TGF‐β1 in human bronchial fibroblasts by binding to HSP90AB1
por: Yi, Erkang, et al.
Publicado: (2023)

Persistence of Neutralizing Antibody Against Dengue Virus 2 After 70 Years from Infection in Nagasaki
por: Ngwe Tun, Mya Myat, et al.
Publicado: (2016)

Neutralizing antibody responses to SARS-CoV-2 in symptomatic COVID-19 is persistent and critical for survival
por: Dispinseri, Stefania, et al.
Publicado: (2021)

Differential persistence of neutralizing antibody against SARS-CoV-2 in post immunized Bangladeshi population
por: Roy, Dipa, et al.
Publicado: (2022)

The impact of CoronaVac on the neutralization breadth and magnitude of the antibody response to SARS-CoV-2 viruses
por: Zhang, Lu, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_3p25rg9781s1oejqq55tqslc7g